Physicians' Academy for Cardiovascular Education

SGLT2i

Recently added learning

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

Type of glycemic control is more important than tight glycemic control

3' education - May 1, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME

Lecture - July 31, 2016 - Asian Interchange on Diabetes - David Fitchett, MD – University of Toronto, Canada

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - David Fitchett, MD – University of Toronto, Canada

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, FL, USA

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome
##FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##FULL_TITLE##

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

3' education - Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

3' education - May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
##FULL_TITLE##

Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##FULL_TITLE##

CV outcomes with medicines to control glycemia: highlights from recently completed trials

3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD

The mechanism of SGLT2 inhibition in glucose control

Nov. 24, 2015
##FULL_TITLE##

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

10' education - Sep. 29, 2015
##FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

10' education - Sep. 29, 2015
##FULL_TITLE##

The mechanism of SGLT2 inhibition in glucose control

3' education - July 24, 2015
##FULL_TITLE##

Cardiovascular effects of glucose lowering: Safety vs Efficacy

3' education - Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar

On demand 10" video

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada
##FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

10' education - Sep. 29, 2015
##FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

10' education - Sep. 29, 2015

Treatment goals for patients with T2DM and CKD

Subtitling in English, German, Italian, Spanish and French

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video.

What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.

Clinical inertia in CKD - What is the rationale for SGLT2i?

Subtitling in English, German, Italian, Spanish and French

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD
A post hoc analysis of EMPA-REG OUTCOME explored potential mediators of the treatment effect of empagliflozin on kidney outcomes.

ERA-EDTA 2021 Prof. Wanner presents the results of a post hoc analysis of EMPA-REG OUTCOME, in which potential mediators of the treatment effect of empagliflozin on kidney outcomes were explored.

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD
Prof. Rossignol presents results from 2 mechanistic studies and analyses from two large SGLT2i trials in HFrEF patients that provide insights in the management of diuretics with SGLT2i therapy.

Prof. Rossignol presents results from two mechanistic studies and analyses from two large SGLT2i trials in HFrEF patients that provide insights in the management of diuretics with SGLT2i therapy.

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD
What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD
A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 m:/min/1.73 m2 was performed. Prof. Bakris shares the results of this analysis,

A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 mL/min/1.73 m² was performed. Prof. Bakris shares the results of this analysis.

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD
Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD
Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effects of SGLT2 inhibitors.

ESC 2020 Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effect of SGLT2 inhibitors.

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD
After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray
Prof. McMurray discusses briefly the outcomes of the EMPEROR-Reduced trial, evaluating the effect of empagliflozin in HFrEF patients, and compares the results to those of the DAPA-HF trial.

ESC 2020 Prof. McMurray discusses briefly the outcomes of the EMPEROR-Reduced trial, evaluating the effect of empagliflozin in HFrEF patients, and compares the results to those of the DAPA-HF trial.

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD
Prof. Wanner presents a case of a patient with CKD who develops diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD
The mechanisms and beneficial cardiorenal effects of SGLT2 inhibitors in diabetic patients are dicussed in this video by Maria Rosa Costanzo, MD

Maria Rosa Constanzo explains the function of SGLT2 in the early proximal tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD
The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD
In this presention by prof. Mark Cooper, an overview is given of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2i, and their effect on kidney outcomes in CKD and DKD patients.

Prof. Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CKD and DKD patients. With question

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD
Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia
Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.

Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD
Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD
SGLT2 inhibitors reduce CV endpoints most likely through a reduction of HF-related events. Prof. Marx discusses potential underlying mechanisms explaining the beneficial effects of this drug class on HF.

SGLT2 inhibitors reduce CV endpoints most likely through a reduction of HF-related events. Prof. Marx discusses mechanisms potentially explaining the beneficial effects of this drug class on HF.

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray
DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME
Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME
Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.

Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME
We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.

We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME
Prof. Agarwal discusses the current standard of care  in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD
Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD
Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada
Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019
Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

ISN-WCN 2019 Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia
Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

ICN-WCN 2019 Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

SGLT2 inhibitor treatment may now be considered in broader T2DM population

AHA 2018 - Chicago, IL, VS

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.
Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME
Prof. Carolyn Lam presents six mechanisms that may underlie the pathophysiology of HFpEF. She discusses why these mechanisms may be targeted for therapy.

HFpEF: The essentials to know Prof. Carolyn Lam presents six mechanisms that may underlie the pathophysiology of HFpEF. She discusses why these mechanisms may be targeted for therapy.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany
Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME
Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME
Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Translation of novel approaches in CVD & diabetes to clinical practice

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Novel diabetes drugs in clinical management: Extending the opportunities

Expert Meeting on CVD & T2DM

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME
Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?

Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?

Clinical trials in diabetes and CVD: What did we learn?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

What are the key mechanisms of CV benefit of novel diabetes drugs?

Expert Meeting on CVD & T2DM

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

What is the science driving CVD and T2DM?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management.

Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.

Diabetes cardiovascular outcome trials

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME
Prof Leiter gives an update of the trials on new antihyperglycemic drugs that have been completed or are ongoing since the FDA mandated demonstration of CV safety. Trials evaluating DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors on CV outcomes are being discussed.

5 Things a cardiologist needs to know about diabetes Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.

Natural history of DM: Focus on micro- and macrovascular complications

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME
Prof. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents.

5 Things a cardiologist needs to know about diabetes Prof. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents.

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA
Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.

Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose  a drug.

Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME
PACE-CME symposium held at ESC 2017 - Heart failure & Diabetes: Time for a more unified approach

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME
SGLT2 inhibition in cardiology: What a cardiologist needs to know

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Type of glycemic control is more important than tight glycemic control

3' education - May 1, 2017 - ESC HF 2017, Paris
Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.

ESC HF 2017 Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris
Prof. Martin Cowie discusses the relationship between diabetes and renal dysfunction and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

Diabetes and renal dysfunction are very common in patients with heart failure. Prof. Martin Cowie discusses the relationship and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris
Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris
Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

Heart failure is the most disabling and deadly complication of diabetes. Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist.

Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents

Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
CV benefit that can be achieved with the new glucose-lowering SGLT2-inhibitor empagliflozin in diabetes

CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.

Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME

Lecture - July 31, 2016 - Asian Interchange on Diabetes - David Fitchett, MD – University of Toronto, Canada
A detailed look at the CV benefits of the EMPA-REG OUTCOME trial and possible underlying mechanisms, and whether other patient populations may also benefit from empagliflozin treatment.

David Fitchett discusses the CV benefits of the EMPA-REG OUTCOME trial in detail, and considers the possible underlying mechanisms, and whether other patient populations may also benefit.

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - David Fitchett, MD – University of Toronto, Canada

Dr. David Fitchett recalls the history of outcome trials of antidiabetic drugs, culminating in the clear CV benefit obtained with an SGLT2 inhibitor recently shown in the EMPA-REG OUTCOME trial.

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Michael Mark illustrates the full trajectory of development of the SGLT2 inhibitor empagliflozin, from finding a therapeutic target through testing clinical effects of the newly developed therapeutic agent.

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, FL, USA

Richard E. Pratley elaborates on the mechanisms of action, effects and outcomes of the many different classes of antidiabetic drugs that are currently available, and how they can be combined to maximise their effect.

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome
Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift?

John McMurray, MD, describes how SGLT2 inhibitors may work in preventing heart failure in diabetes.

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome
SGLT-2 inhibitors in T2DM management: current position & future promise

Silvio Inzucchi reviews the role of new medications for diabetes, and in particular the SGLT2 inhibitors, and the results of the EMPA-REG OUTCOMR study

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##KEY_PHRASE##

Good glycaemic control can now be achieved with a lower risk of hypoglycaemia than before. Prof. Groop elaborates on the evidence on whether improving glycaemic control with DPP-4 inhibitors translates into a reduction of renal complications.

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##KEY_PHRASE##

Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

3' education - Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
##KEY_PHRASE##

Recent outcome trials of novel antidiabetic drugs shed new light on why diabetes patients develop heart disease. Naveed Sattar predicts how this may change diabetes management.

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

ESC HF 2016 The results of the EMPA-REG outcome trial have changed views on how SGLT2 inhibition may yield benefit. Naveed Sattar describes the emerging mechanistic concept based on the latest trial data.

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

ESC HF 2016 David Fitchett discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
New therapies for type 2 diabetes show CV event reduction, in addition to their glucose-lowering effect.

Silvio Inzucchi summarises recent developments in treatment of type 2 diabetes. Some new agents yield clear CV event risk reduction, while older glucose-lowering medication only had a moderate effect on CV events.

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##KEY_PHRASE##

Dr Fitchett provides his perspective on the potential impact of the EMPA REG outcomes trial on the management of T2DM by cardiologists.

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

3' education - May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands

Prof Lambers Heerspink reviews potential mechanisms beyond glucose lowering, explaining the positive cardiovascular outcomes of SGLT2 inhibition as seen in the EMPA REG Outcomes trial.

Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##KEY_PHRASE##

Prof Stephen Wiviott (Boston, MA, USA) summarises recent advances in development of antidiabetic agents that not only lower glucose but also reduce CV events.

CV outcomes with medicines to control glycemia: highlights from recently completed trials

3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD
##KEY_PHRASE##

In response to a requirement of regulatory bodies for antidiabetic trials to now include CV outcomes assessment, data of 5 such outcomes trials are now available. Dr. McGuire (Dallas, TX, USA) summarises the results.

The mechanism of SGLT2 inhibition in glucose control

Nov. 24, 2015

A mechanism of action animation of SGLT2-inhibition, a diabetes therapy that directly targets glucose by reducing renal glucose reabsorption, independently of beta cell function and insulin resistance

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##KEY_PHRASE##

AHA 2015 Prof. Silvio Inzucchi (Yale Diabetes Center, New Haven, CT, USA) presented the HF outcomes on the large CV outcome EMPA-REG OUTCOME trial, which evaluated treatment with SGLT2-inhibitor empagliflozin in patients with diabetes.

SGLT2 inhibitor outcome trials: Future opportunities

Dr David Fitchett

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##KEY_PHRASE##

Dr Fitchett discusses the unmet glycemic control needs, the ongoing clinical trials with SGLT2 inhibitors and the EMPA-REG OUTCOME trial

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Prof Silvio E Inzucchi, Yale Diabetes Center, New Haven, CT, USA

10' education - Sep. 29, 2015
##KEY_PHRASE##

Prof Inzucchi provides an overview on SGLT2 inhibition, how they work and what are the potential pathways for cardiovascular benefits

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

Prof John Betteridge, London UK

10' education - Sep. 29, 2015
##KEY_PHRASE##

Prof John Betteridge reviews the rationale for cardiovascular risk factor management in diabetes

The mechanism of SGLT2 inhibition in glucose control

3' education - July 24, 2015
##KEY_PHRASE##

A mechanism of action animation of SGLT2-inhibition, a diabetes therapy that directly targets glucose by reducing renal glucose reabsorption, independently of beta cell function and insulin resistance

Cardiovascular effects of glucose lowering: Safety vs Efficacy

3' education - Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##KEY_PHRASE##

Dr. Inzucchi, New Haven, provides his perspective on current diabetes therapies and ongoing trials with DPP4 and SGLT2 inhibitors on cardiovascular safety and/or benefits

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##KEY_PHRASE##

Prof. Naveed Sattar, Glasgow, UK provides his view on the potential role of novel diabetes drugs in CV risk management